CureVac N.V. (CVAC)
| Market Cap | 2.12B |
| Revenue (ttm) | 105.39M |
| Net Income (ttm) | -132.81M |
| Shares Out | 190.28M |
| EPS (ttm) | -0.70 |
| PE Ratio | n/a |
| Forward PE | 9.17 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 83,856 |
| Open | 10.82 |
| Previous Close | 10.74 |
| Day's Range | 10.74 - 11.12 |
| 52-Week Range | 5.63 - 20.50 |
| Beta | 2.50 |
| Analysts | Buy |
| Price Target | 16.76 (+50.99%) |
| Earnings Date | n/a |
About CVAC
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncyt... [Read more]
Financial Performance
In 2021, CureVac's revenue was 102.99 million, an increase of 110.74% compared to the previous year's 48.87 million. Losses were -411.72 million, 218.9% more than in 2020.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for CVAC stock is "Buy." The 12-month stock price forecast is $16.76, which is an increase of 50.99% from the latest price.
News
CureVac Welcomes Myriam Mendila as New Chief Development Officer
Dr. Mendila joins CureVac as Chief Development Officer with more than 20 years of global industry experience TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / February 1, 2023 / CureVac N.V. (Nasdaq:CVA...
CureVac Named as One of the World's Most Dynamic Innovators by LexisNexis(R)
CureVac recognized as a Top 100 innovator in acknowledgment of the company's innovative strength and extensive intellectual property portfolio The company holds one of broadest intellectual property p...
CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs
Continued technology platform validation with extended preliminary data from older adults in ongoing Phase 1 studies in COVID-19 and flu COVID-19: monovalent modified mRNA construct CV0501 successfull...
UBS: CureVac has a ‘potentially competitive mRNA platform'
CureVac's CVAC, +8.44% promising Phase 1 data for flu and COVID-19 vaccine candidates is a signal to investors that its messenger RNA technology is, in fact, competitive, according to UBS Securities a...
UBS reveals a biotech stock that can nearly double from here
Shares of CureVac BV (NASDAQ: CVAC) have already almost doubled year-to-date but a UBS analyst says the stock still has a lot more room to the upside.
7 Biotech Stocks That Will Make You Rich in 10 Years
If you have the patience to go through wild undulations, then you may be a candidate for biotech stocks that will make you rich in 10 years. Even among the most established biotechnology firms, they'r...
Moderna, CureVac and Ocugen offer updates on COVID vaccines, while China cracks down on critics of government's pandemic response
A flurry of announcements relating to COVID vaccines dominated headlines on the pandemic on Monday, with Moderna telling investors it expects to generate some $5 billion in sales in 2023.
CureVac Appoints Alexander Zehnder as CEO From April 1, 2023
Dr. Franz-Werner Haas to complete successful tenure as CEO by March 31, 2023 Dr. Alexander Zehnder to succeed Dr. Haas as new CEO, joining from Sanofi on April 1, 2023 TÜBINGEN, GERMANY and BOSTON, MA...
CureVac shares surge after preliminary data on COVID-19 and flu shots
CureVac CVAC, +29.47% shares rocketed 26% in premarket trade as the German company said preliminary data from its early stage trial for its COVID-19 and seasonal flu shots had positive results to adva...
CureVac (CVAC) Stock Rises 25% on Positive Data for Covid-19 and Flu Vaccines
Amid a strong showing on Wall Street prior to the weekend, shares of CureVac (NASDAQ: CVAC) stock popped dramatically northward on positive data for its coronavirus and flu vaccines. Preliminary clin...
CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs
Promising COVID-19 and flu modified mRNA vaccine candidates identified based on positive preliminary data from ongoing Phase 1 studies All candidates use CureVac's advanced second-generation mRNA back...
CureVac Members of Management Sell Shares to Cover Tax Obligations from Long Term Incentive Program
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / December 14, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger...
Wall Street Analysts Believe CureVac N.V. (CVAC) Could Rally 139%: Here's is How to Trade
The consensus price target hints at a 139% upside potential for CureVac N.V. (CVAC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estim...
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2022 and Provides Business Update
Delivering on broad second-generation vaccine development program with expansion into modified mRNA technology in collaboration with GSK Phase 1 studies in influenza and COVID-19 on track to deliver c...
CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102
Data confirm CV8102's safety and ability to strongly mobilize the immune system against tumors Final data of complete Phase 1 dose-escalation and expansion study expected in H1 2023 TÜBINGEN, GERMANY ...
CureVac to Report Third Quarter and First Nine Months 2022 Financial Results and Business Updates on November 16, 2022
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 10, 2022 / CureVac N.V. (NASDAQ:CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonu...
Bet on These 4 Biotech Stocks With Bright Prospects
New drug approvals and pipeline development should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position AGEN, CVAC, IMCR and DVAX well am...
CureVac is focusing on mRNA cancer vaccines, CFO says
Pierre Kemula, CureVac CFO, discusses the future of the technology.
Here's Why CureVac N.V. (CVAC) is Poised for a Turnaround After Losing 20.9% in 4 Weeks
CureVac N.V. (CVAC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.
CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business Update
Delivering on broad 2022 second-generation vaccine development program with expansion into modified mRNA technology in collaboration with GSK; new candidates in COVID-19 and influenza enter clinical s...
CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate
Phase 1 dose-escalation study to be conducted at clinical sites in the U.S., the UK, Australia, and the Philippines Milestone demonstrates CureVac's continued execution on comprehensive clinical progr...
BioNTech, Pfizer sue CureVac in U.S. over COVID-19 vaccine patent claims
COVID-19 vaccine maker BioNTech said on Tuesday that it and partner Pfizer have filed a complaint with the U.S. District Court in Massachusetts, seeking a judgment that they did not infringe U.S. pate...
Wall Street Analysts Predict a 96% Upside in CureVac N.V. (CVAC): Here's What You Should Know
The mean of analysts' price targets for CureVac N.V. (CVAC) points to a 96.4% upside in the stock.
CureVac Files COVID-19 Vaccine Patent Infringement Lawsuit Against BioNTech
CureVac N.V. (NASDAQ: CVAC) has moved to assert its intellectual property rights, accumulated over two decades of pioneering work in mRNA technology, which contributed to COVID-19 vaccine development.